DELRAY BEACH, Fla., Dec. 17, 2024 /PRNewswire/ -- The global artificial intelligence in clinical trials market is forecasted to grow steadily from US$1.20 billion in 2023 to US$1.35 billion in 2024, ultimately reaching an impressive US$2.74 billion by 2030, driven by a robust CAGR of 12.4%. Some of the key elements fueling the expansion of the AI in clinical trials market, are the high rate of clinical trial failures, the increasing need of anticipating drug pharmacokinetics, pharmacodynamics, and management of toxicity. According to a research article published by the National Library of Medicine in February 2022, the drug discovery and development process takes about 10-15 years for a new drug to be approved for clinical use. And 90% of the drug candidates fail during the phases I, II, and III of clinical trials and drug approvals. The reasons that may result in failure include but not limited to effectiveness in a clinical setting, high levels of toxicity that cannot be managed, suboptimal drug-like characteristics, a lack of real commercial drivers, and poor strategic design

PASADENA, Calif., Aug. 1, 2023 /PRNewswire/ -- Texas Tech University Health Sciences Center (TTUHSC) and Deep 6 AI announced a collaboration, joining forces to integrate artificial intelligence (AI) within TTUHSC's electronic medical record (EMR) system to improve patient access to clinical trials.Texas Tech University Health Sciences Center Partners with Deep 6 AI to Launch an AI Program for Clinical TrialsTTUHSC will use Deep 6 AI to precision-match patients to their clinical trials in real time. This process will allow researchers to find the right patients for their trials in minutes, which will greatly reduce the workload on their staff. By using these AI tools, TTUHSC researchers will ultimately give more patients access to participate in clinical trials and will be able to use any resulting therapies to treat patients even faster. This partnership further expands the Deep 6 AI ecosystem, which consists of millions of unique patient records and thousands of trial sites accessible to sponsors for their research."Clinical trials are extremely valuable because they provide patients with opportunities to access therapies they otherwise would not have access to," John Griswold, M.D., executive director of the TTUHSC Clinical Research Institute said. "This collaboration with Deep 6 AI will enhance our ability to bring cutting-edge treatments to our community."One of the most time-consuming components of clinical research is finding patients who match the specific criteria needed for the study